Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic or is surgically unresectable. * Radiographically measurable disease (per RECIST v1.1 or RANO for primary brain tumors). Tumor lesions located in a previously irradiated area or in an area subjected to other loco-regional therapy are considered measureable if progression has been clearly demonstrated in the lesion. * Documentation of an FGFR1-3 gene mutation or translocation. * Objective progression after at least 1 prior therapy and no therapy available that is likely to provide clinical benefit. Participants who are intolerant to or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit. * Eastern Cooperative Oncology Group performance status 0 to 2. * Baseline archival tumor specimen (if less than 24 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. Must be a tumor block or approximately 15 unstained slides from biopsy or resection of primary tumor or metastasis. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Prior receipt of a selective FGFR inhibitor in the past 6 months. * Receipt of anticancer medications or investigational drugs for any indication or reason within 28 days before first dose of pemigatinib. * Cannot be a candidate for potentially curative surgery. * Current evidence of clinicall…